Thursday , July 20 2017
Home / Technology & Devices

Technology & Devices

New Imaging Technique Able to Watch Molecular Dynamics of Neurodegenerative Diseases

WASHINGTON — Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. The new technique reveals a sample’s chemical makeup as well as the orientation of molecules making up …

Read More »

New Data Network for Huntington’s Disease Research

Huntington’s disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to cell death in neurons in the brain resulting in gradual physical, mental and emotional changes, and ultimately death. Those born to a parent with Huntington’s disease have …

Read More »

Simple Test Predicts Return of Bladder Cancer

Scientists have devised a simple test for an earlier and more accurate warning of returning bladder cancer than existing methods, according to research* published in the British Journal of Cancer today (Friday). Researchers from the University Hospital of Lyon tested the urine of 348 bladder cancer patients for a faulty protein called …

Read More »

The First Physician in the World to Study Computed Tomography Laser Mammography (CTLM) as an Adjunct to Mammography in Dense Breasts

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among women in the United States. According the Breast Cancer Facts and Figures reported by American Cancer Society, in 2017, approximately 252,710 new cases of invasive breast cancer and 60,290 new cases of in …

Read More »

Cystic Fibrosis Patients and Physicians Use Shared Decision-Making Tool to Determine Regimens

CINCINNATI–Physician-researchers at the University of Cincinnati have developed a computerized decision-making model to promote shared decision-making with cystic fibrosis patients. The tool takes into account patients’ preferences for measures of lung function and health along with the latest medical evidence for effective treatment to help patients prioritize home treatments. Mark …

Read More »

Liquid Biopsies: A Non-Invasive Look at Treatment Response

Barcelona, Spain, 30 June 2017 – A new study, to be presented at the ESMO 19th World Congress on Gastrointestinal Cancer, shows that so-called “liquid biopsies”, blood tests that detect circulating tumor DNA (ctDNA), may not only sound an early alert that a treatment’s effect is diminishing, but may also …

Read More »

Pfizer Enters Feasibility Study Agreement Evaluating Alcyone’s Pulsar Technology for Use in Gene Therapy Targeting CNS Disorders

LOWELL, Mass., June 29, 2017 /PRNewswire/ — Alcyone Lifesciences, Inc., a leader in precision advanced central nervous system (CNS) delivery systems announced that it has entered into a feasibility study agreement with Pfizer Inc. (NYSE: PFE) in the area of genetic therapy targeting rare and orphan neurological disorders. The feasibility …

Read More »

Janssen to Utilize Adaptive’s NGS-Based clonoSEQ Assay to Measure MRD in Darzalex Multiple Myeloma Trials

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has partnered with Janssen Biotech, Inc. to utilize Adaptive’s NGS-based clonoSEQ Assay for measuring minimal residual disease (MRD) in patients with Multiple Myeloma …

Read More »

Johnson & Johnson Innovation Announces New Collaborations Advancing Ground-Breaking Biomedical Innovation

NEW BRUNSWICK, N.J., June 15, 2017 /PRNewswire/ — Johnson & Johnson Innovation LLC today announced new collaborations that seek to develop potential treatments for diseases in urgent need of solutions, including obesity and related complications, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), and rheumatoid arthritis, and advance cutting-edge …

Read More »

Dragonfly Therapeutics and Celgene Collaborate on Novel NK Cell-Based Immunotherapies using Dragonfly’s TriNKET technology

CAMBRIDGE, Mass., June 12, 2017 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a global strategic collaboration with Celgene Corporation and its affiliates (“Celgene”) to discover, develop and commercialize innovative immuno-oncology treatment options for patients with hematological malignancies based on Dragonfly’s Natural Killer (“NK”) cell based TriNKET™ technology platform. The …

Read More »